Eli Lilly in advanced clinical trials for its weight-loss pill
Eli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess its safety and efficacy compared to insulin glargine in individuals with type-two diabetes and obesity or overweight at an increased cardiovascular risk. The company's spokesperson in India mentioned ongoing clinical studies on novel products, including orforglipron. (Source: The Economic Times)
Source: The Economic Times - March 28, 2024 Category: Consumer Health News Source Type: news
Improving Diabetes Care Through Reduced Insulin Use in Nursing Homes
Reference: Umpierrez GE, Cardona S, Chachkhiani D, Fayfman M, Saiyed S, Wang H, Vellanki P, Haw JS, Olson DE, Pasquel FJ, Johnson TM 2nd. A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Patients With Type 2 Diabetes in Long-term Care and Skilled Nursing Facilities: Linagliptin-LTC Trial. J Am Med Dir Assoc 2018;19(5):399 –404.e3. (Source: Caring for the Ages)
Source: Caring for the Ages - October 31, 2023 Category: Health Management Authors: By Omid Salaami Tags: Pragmatic Research Source Type: news
Sanofi to offer insulin product for $35 to all Americans through GoodRx
Sanofi Lantus brand insulin pens are arranged for a photograph in the Brooklyn borough of New York, U.S., on Friday, April 5, 2019. Americans, regardless of their insurance status, can now access Sanofi 's most widely prescribed insulin for $35 through the prescription drug savings company GoodRx…#sanofilantus #brooklyn #sanofi #lantus #cvs #walmart #elililly #novonordisk #pharma #phreesialifesciences (Source: Reuters: Health)
Source: Reuters: Health - October 19, 2023 Category: Consumer Health News Source Type: news
Tirzepatide With Insulin Glargine Improves Type 2 Diabetes Tirzepatide With Insulin Glargine Improves Type 2 Diabetes
Adding tirzepatide to insulin glargine leads to greater improvements in A1c, body weight, and less hypoglycemia compared with prandial insulin lispro show data simultaneously published in JAMA.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 3, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
ADA: Glycemic Control Up With Weekly Icodec Versus Daily Insulin Glargine
MONDAY, June 26, 2023 -- For adults with type 2 diabetes, glycemic control is significantly better with once-weekly icodec than once-daily insulin glargine U100, according to a study published online June 24 in the New England Journal of Medicine to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 26, 2023 Category: Pharmaceuticals Source Type: news
Once-Weekly Insulin Icodec Bests Daily Insulin Options for Type 2 Diabetes
(MedPage Today) -- SAN DIEGO -- Investigational once-weekly insulin icodec outperformed once-daily insulin glargine U100 when it came to glycemic control in type 2 diabetes, the phase IIIa ONWARDS 1 trial found.
Over the course of 52 weeks... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 25, 2023 Category: Primary Care Source Type: news
Will Senate Hearing Expose PBMs ’ Unscrupulous Drug Pricing Tactics?
Today , Sen. Bernie Sanders, I-Vt., will haul executives from three insulin manufacturers and three pharmacy benefit managers before the Senate Health, Education, Labor and Pensions Committee for a hearing on "the need to make insulin affordable for all Americans." Sen. Sanders is sure to call the…#berniesanders #elilillyandcompany #novonordisk #helpcommittee #expressscripts #optumrx #formulary #lantus #insulin #healthforum (Source: Reuters: Health)
Source: Reuters: Health - May 10, 2023 Category: Consumer Health News Source Type: news
Once-Weekly Insulin Icodec Wins; Wegovy Heart Data Soon; AACE's T2D Algorithm Update
(MedPage Today) -- Compared with once-daily insulin glargine U100, once-weekly icodec performed similarly for glycemic control, but needed fewer basal insulin injections and a lower bolus insulin dose, and had no increase in hypoglycemic rates... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - May 9, 2023 Category: Endocrinology Source Type: news
Sanofi launches new long-acting insulin drug in India
Soliqua is indicated as treatment to improve glycemic control as an adjunct to diet and exercise, in adults with obesity and type 2 diabetes who are insufficiently controlled on oral or injectable therapies.It comes in once daily dosing of pre-filled pens in fixed-ratio combination of 10-40 and 30-60 of insulin glargine and lixisenatide. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 27, 2023 Category: Pharmaceuticals Source Type: news
Sanofi to Cut US Price of Its Most-Prescribed Insulin by 78% Sanofi to Cut US Price of Its Most-Prescribed Insulin by 78%
Sanofi said on Thursday it will cut US list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 17, 2023 Category: Consumer Health News Tags: Pharmacist News Source Type: news
Sanofi Is Now the Third Insulin Producer to Slash Prices
Sanofi will cut the U.S. list price of two of its insulins, making it the third major producer of the diabetes medicine to recently slash prices.
French pharmaceutical maker Sanofi will reduce the U.S. list price of Lantus, its most-prescribed insulin, by 78%, according to a statement Thursday. The company will also reduce the list price of Apidra by 70%.
“We are pleased to see others join our efforts to help patients as we now accelerate the transformation of the U.S. insulin market,” said Olivier Bogillot, the head of U.S. general medicines. “Our decision to cut the list price of our lead insulin needs ...
Source: TIME: Health - March 17, 2023 Category: Consumer Health News Authors: Ilena Peng/Bloomberg Tags: Uncategorized bloomberg wire Drugs healthscienceclimate Source Type: news
Sanofi becomes latest drugmaker to announce insulin price cuts, capping cost at $35 for the privately insured
Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday. The change is effective January 1. (Source: CNN.com - Health)
Source: CNN.com - Health - March 17, 2023 Category: Consumer Health News Source Type: news
Sanofi to cut US price of its most-prescribed insulin by 78%
[1/2] A pharmacist holds a box of the drug Lantus SoloStar, made by Sanofi Pharmaceutical, at a pharmacy in Provo, Utah, U.S. January 9, 2020. REUTERS/George Frey/File Photo March 16 (Reuters) - Sanofi SA (SASY.PA) said on Thursday it will cut U.S. list prices for its most-prescribed insulin…#lantus #solostar #sanofipharmaceutical #provo #utah #novonordisk #elilillyandco #medicare #sanofi #rivalnovonordisk (Source: Reuters: Health)
Source: Reuters: Health - March 17, 2023 Category: Consumer Health News Source Type: news
Here ’s How the Other Major Insulin Makers Are Responding After Eli Lilly’s Price Cap
Facing pressure to curb diabetes-treatment costs, Eli Lilly & Co. announced on March 1 that it is slashing insulin prices and immediately capping the out-of-pocket cost of all of its insulins at $35 a month. President Joe Biden, who made insulin costs a focus of his State of the Union speech last month, praised the move by Lilly and called on other drugmakers to also lower insulin prices.
The price cuts by the Indianapolis-based Lilly, one of the world’s top three insulin producers, are expected to provide critical relief to the millions of Americans who rely on the medicine to control their blood sugar levels. S...
Source: TIME: Health - March 2, 2023 Category: Consumer Health News Authors: Nik Popli Tags: Uncategorized Drugs News Team Source Type: news
Lilly to cut price of insulin for people with commercial health insurance
Eli Lilly & Co. LLY said Wednesday that is capping out-of-pocket insulin costs to $35 for people with commercial health insurance at certain retail pharmacies and it is also lowering the prices of most its insulins, such as pricing non-branded Insulin Lispro at $25 a vial. The company also plans…#elilillyco #lly #insulinlispro #humalogandhumulin #lilly #lantus (Source: Reuters: Health)
Source: Reuters: Health - March 1, 2023 Category: Consumer Health News Source Type: news
